TY - JOUR
T1 - Clinical efficiency and safety of the oticon medical neuro cochlear implant system
T2 - a multicenter prospective longitudinal study
AU - Schramm, David
AU - Chen, Joseph
AU - Morris, David P.
AU - Shoman, Nael
AU - Philippon, Daniel
AU - Cayé-Thomasen, Per
AU - Hoen, Michel
AU - Karoui, Chadlia
AU - Laplante-Lévesque, Ariane
AU - Gnansia, Dan
N1 - Publisher Copyright:
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/9
Y1 - 2020/9
N2 - Objective: This prospective longitudinal cohort study at six tertiary referral centers in Canada and Denmark describes the clinical efficiency and surgical safety of cochlear implantation with the Oticon Medical Neuro cochlear implant system, including the Neuro Zti implant, the EVO electrode array, and the Neuro One sound processor. Methods: Patients were adult cochlear implant candidates with bilateral sensorineural hearing loss. Results: The mean HINT scores in quiet pre-operatively and at 3, 6, and 12 months post-activation were 13%, 58%, 67%, and 72%, respectively, and in noise (+10 dB SNR) 13%, 46%, 53%, and 59%, respectively. The mean improvement from baseline to 6 months post-activation was 54% in quiet and 40% in noise. The surgical major complication incidence rate was 0% and the post-surgical major complication incidence rate (until 12 months post-activation) was 4%. There was no adverse event that was fatal, that required explantation, or that resulted in sound processor nonuse, and no implant failure. Conclusion: Cochlear implantation with the Oticon Medical Neuro system enables speech identification both in quiet and in noise and audiologic outcomes continue to improve in the year following activation. No substantial adverse events occurred during the surgical implantation procedure and during the 12 months post-activation.
AB - Objective: This prospective longitudinal cohort study at six tertiary referral centers in Canada and Denmark describes the clinical efficiency and surgical safety of cochlear implantation with the Oticon Medical Neuro cochlear implant system, including the Neuro Zti implant, the EVO electrode array, and the Neuro One sound processor. Methods: Patients were adult cochlear implant candidates with bilateral sensorineural hearing loss. Results: The mean HINT scores in quiet pre-operatively and at 3, 6, and 12 months post-activation were 13%, 58%, 67%, and 72%, respectively, and in noise (+10 dB SNR) 13%, 46%, 53%, and 59%, respectively. The mean improvement from baseline to 6 months post-activation was 54% in quiet and 40% in noise. The surgical major complication incidence rate was 0% and the post-surgical major complication incidence rate (until 12 months post-activation) was 4%. There was no adverse event that was fatal, that required explantation, or that resulted in sound processor nonuse, and no implant failure. Conclusion: Cochlear implantation with the Oticon Medical Neuro system enables speech identification both in quiet and in noise and audiologic outcomes continue to improve in the year following activation. No substantial adverse events occurred during the surgical implantation procedure and during the 12 months post-activation.
UR - http://www.scopus.com/inward/record.url?scp=85092127907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092127907&partnerID=8YFLogxK
U2 - 10.1080/17434440.2020.1814741
DO - 10.1080/17434440.2020.1814741
M3 - Article
C2 - 32885711
AN - SCOPUS:85092127907
SN - 1743-4440
VL - 17
SP - 959
EP - 967
JO - Expert Review of Medical Devices
JF - Expert Review of Medical Devices
IS - 9
ER -